Belgian clinical-stage biotech (formerly Galapagos) developing immunology drugs, led by a BCMA/CD3 T-cell engager, with cell therapy being wound down.
Belgian clinical-stage biotech (formerly Galapagos) developing immunology drugs, led by a BCMA/CD3 T-cell engager, with cell therapy being wound down.
Has no product sales after selling its approved drug filgotinib to Alfasigma in 2024, so it lives off a large cash balance. It is rebuilding around autoimmune treatments: it took on Ouro Medicines' T-cell engager together with Gilead, its major shareholder, and is winding down cell-therapy operations. Renamed from Galapagos in 2026.
Moat: narrow (IP / patents). Rights to a clinical-stage T-cell engager plus a large cash buffer; no approved products.
Headquarters: Mechelen, Belgium · Founded: 1999 · Employees: 452
Size Lakefront Biotherapeutics (LKFT.AS) is a Netherlands Health Care company (Biotechnology) with a market value of $2.26B, the 40th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €31.32 on 18 Nov 2026.
Performance Over six months the shares gained 31.4%, against -10.8% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue grew 223.1% over the last twelve months (peer median +4.1%); the operating margin is 64.5% (peer median -19.9%).
Capital Return on invested capital runs 37.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €927M | €1.11B | €276M | €240M | €241M |
| Revenue growth | — | +304% | +15% | -1% | — |
| Gross profit | €909M | €1.03B | €192M | €204M | €211M |
| EBITDA | n/a | €522M | -€179M | -€91.9M | -€102M |
| Net income | €796M | €321M | €74.1M | €212M | -€218M |
| Free cash flow | -€142M | -€211M | -€307M | -€410M | -€525M |
| Capital expenditure | €1.91M | €13.9M | €82.1M | €19.3M | €36.9M |
| Total debt | €3.10M | €6.92M | €11.7M | €9.60M | €21.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Lakefront Biotherapeutics LKFT.AS | $2.26B | +31% | +223% | 64% | n/a | n/a |
| argenx SE Sponsored ADR ARGX | $59.1B | +17% | +71% | 29% | 10.3× | 11.7% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| Amgen AMGN | $240B | +34% | +9% | 36% | 7.2× | 1.6% |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | LKFT.AS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.2% | -4.9% | 3rd highest of 21 |
| 6-month return | +31.4% | -10.8% | 6th highest of 20 |
| Distance from 52-week high | -2.4% | -35.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +223.1% | +4.1% | highest of 17 |
| Operating margin | 64.5% | -19.9% | highest of 15 |
| ROIC minus cost of capital | +37.1 pp | -11.0 pp | 2nd highest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |